Friday, July 31, 2026
← Back to archivePolicy
Policy•STAT News•Jul 31, 2026
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
background ▾
- •FDA's platform technology designation tool, created by Congress via FDORA 2022 to streamline rare disease drug development, is being misapplied with inconsistent risk-benefit logic across disease subtypes and patient populations using the same technology
- •Three patient deaths on a shared viral vector led to blanket clinical holds across all programs, but subsequent selective lifting of holds for ambulatory DMD patients while maintaining holds for ambulatory LGMD2E/R4 patients demonstrates regulatory inconsistency that confuses sponsors and frustrates patient communities
- •Monitor whether FDA clarifies platform technology designation guidance and clinical hold criteria for rare disease gene therapies under new leadership, and whether Congress or advocacy groups push for regulatory reform to restore intended flexibility and efficiency
Sarepta TherapeuticsLGMD2E/R4 gene therapyDuchenne muscular dystrophy gene therapy
→ Read original articlePolicy•STAT News•Jul 30, 2026
Capricor’s data clash and a fugitive in the C-suite
background ▾
- •Capricor's DMD drug faces FDA advisory committee scrutiny over data integrity, suggesting potential approval challenges
- •Broader question raised about FDA consistency in DMD drug evaluation standards across different sponsors
Capricor TherapeuticsReplimmuneGlaxoSmithKline
→ Read original articlePolicy•STAT News•Jul 31, 2026
Opinion: We once praised the American Diabetes Association’s courage. How things have changed
background ▾
- •ADA security removed five physicians from its annual conference and confiscated materials distributing an opinion piece critical of Trump administration science policy, claiming a need to maintain 'nonpartisan environment'
- •The move has triggered calls from over 200 ADA members for leadership resignations, investigations, and a formal apology, threatening the organization's credibility on editorial independence
- •The incident represents a concerning reversal from the ADA's 2015 defense of editorial integrity against a defamation suit, raising questions about organizational governance and institutional courage under political pressure
American Diabetes Association
→ Read original articlePolicy•STAT News•Jul 31, 2026
Syphilis spreads while researchers contend with federal constraints and a drug shortage
background ▾
- •NIH foreign research restrictions are directly impairing infectious disease surveillance and response in a border region with significant cross-population movement, creating a regulatory-public health conflict
- •Intramuscular penicillin shortage is preventing full treatment of confirmed syphilis cases in a vulnerable population, representing a critical market access/supply chain failure for an essential antibiotic
- •Watch for whether NIH revises cross-border research policies in response to this documented public health gap, and whether penicillin supply constraints persist or resolve
University of California, San DiegoPlanned Parenthoodpenicillin (intramuscular)
→ Read original articlePolicy•KFF•Jul 30, 2026
Health and Health Care Experiences of Uninsured Immigrants
background ▾
- •The 2025 reconciliation law will eliminate health coverage for an estimated 1.4 million lawfully present immigrants by 2034, creating a major public health and access crisis in an already vulnerable population
- •Uninsured immigrant adults skip or postpone care at 50% vs. 26% for insured counterparts, with cost cited as the primary barrier; 18% report worsening health as a result of delayed care
- •Watch for implementation timelines and state-level responses to federal coverage restrictions, as well as real-world health outcome data as coverage losses take effect; potential litigation challenges to eligibility restrictions
Market Access
Market Access•Fierce Biotech•Jul 31, 2026
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
background ▾
- •Apnimed raised $192M in IPO to fund Oxnimbi launch—exceeding original $134.6M estimate and reflecting strong biotech market appetite for sleep apnea therapies
- •Oxnimbi Phase 3 data showed 46.8% reduction in apneic events and represents first OSA-specific approved medicine if FDA approval is granted by Feb 2027, differentiating it from Zepbound's obesity-restricted label
- •Watch for FDA approval decision by February 2027 and subsequent commercial execution; competitive dynamics with Eli Lilly's Zepbound and potential market penetration against entrenched CPAP devices
ApnimedEli LillyPfizerOxnimbiAD109Zepbound
→ Read original articleMarket Access•Fierce Biotech•Jul 30, 2026
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
background ▾
- •Labcorp raised full-year 2026 revenue guidance despite Q2 miss, signaling confidence in sustained diagnostics and biopharma lab services growth
- •Launch of Marker by Labcorp Genetic Health Panel represents expansion into direct-to-consumer genetic testing, positioning the company in the high-growth precision medicine and consumer health markets
- •Watch for uptake of the new DTC genetic panel and whether it materially contributes to revenue growth in coming quarters; monitor competitive responses from other lab service providers
Labcorp
→ Read original articleMarket Access•Fierce Biotech•Jul 30, 2026
GSK pens $110M biological datasets pact with AI biotech Relation
background ▾
- •GSK is investing $110M to access proprietary human cellular perturbation datasets and Relation's MORGAN foundation model, signaling institutional confidence in AI-enabled early drug discovery
- •This is the third GSK-Relation deal in ~18 months, alongside Relation's concurrent $1.7B+ milestone deal with Novartis, indicating these datasets and models are gaining traction among major pharma
- •Monitor whether this collaboration yields validated drug targets or clinical candidates in GSK's priority areas (immunology, metabolic, bone, fibrotic diseases); success will validate the biological relevance and predictive power of perturbation data in foundation models
GSKRelationNovartis
→ Read original articleMarket Access•Endpoints News•Jul 30, 2026
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
background ▾
- •Regeneron and Sanofi are discussing potential expansion of their partnership beyond the current Dupixent portfolio
- •No specific drug candidates or therapeutic areas have been identified, indicating this remains in exploratory phase
RegeneronSanofiDupixent (dupilumab)
→ Read original articleMarket Access•Fierce Biotech•Jul 30, 2026
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
background ▾
- •BMS explicitly signals it will not engage in opportunistic M&A and will only pursue deals in well-known therapeutic areas with strong science and clear financial value creation
- •The company discontinued three clinical-stage programs in a portfolio review, suggesting more disciplined capital allocation despite ample financial capacity
Bristol Myers SquibbEli LillyMerck & Co.BMS-986458milvexianadmilparant
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 30, 2026
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
background ▾
- •Replimune's RP1 cleared a critical FDA advisory committee hurdle after two rejections, with the majority voting that despite trial design flaws, efficacy signals warrant approval in an underserved patient population
- •The FDA's core concerns centered on Ignyte's lack of control arm and patient population heterogeneity, which Replimune argues were necessary given ethical constraints of studying patients who had failed PD-1 therapy
- •Watch for the FDA's final decision by August 2; approval would validate the oncolytic virus + checkpoint inhibitor combination strategy and provide the first systemic treatment option for PD-1 refractory melanoma patients beyond complex/inaccessible TIL therapy
ReplimuneBristol Myers SquibbAmgenRP1vusolimogene oderparepvecTudriqev
→ Read original articleClinical Trials•Fierce Biotech•Jul 30, 2026
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
background ▾
- •Adept trial data now expected in early 2027 spread across the year, not 2026—second major delay for Cobenfy's pivotal Alzheimer's psychosis program
- •Slower relapse event accrual and enrollment pace could indicate drug efficacy or trial quality measures, but true signal remains masked by blinded design
- •Second major BMS pivotal program delayed: milvexian (Factor XIa inhibitor) Librexia-AF trial now reads out Q1 2027 instead of 2026, both attributed to event accrual pace
Bristol Myers SquibbPfizerCobenfymilvexianLibrexia-AF
→ Read original articleClinical Trials•Endpoints News•Jul 31, 2026
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
background ▾
- •Latigo's non-opioid pain drug met its Phase 2b primary endpoint for acute pain reduction, de-risking advancement toward Phase 3 and potential commercialization
- •The company is explicitly positioning this asset to compete with Vertex's established pain franchise, indicating confidence in market opportunity and differentiation
- •Detailed efficacy/safety data, mechanism of action, dosing regimen, and timeline to Phase 3 initiation are not yet disclosed
Latigo BiotherapeuticsVertex Pharmaceuticals
→ Read original articleClinical Trials•STAT News•Jul 31, 2026
Opinion: What a recent op-ed got wrong about our Covid study
background ▾
- •The underlying study found NPIs (mask mandates, mobility restrictions) associated with lower infection rates but did not establish statistical association with deaths
Clinical Trials•Endpoints News•Jul 30, 2026
Replimune scores win as FDA advisors back melanoma treatment
background ▾
- •FDA advisory committee voted in favor of Replimune's melanoma treatment efficacy and supporting clinical trial data
- •Positive advisory opinion significantly de-risks the pathway to FDA approval and sets stage for potential label expansion in melanoma
- •Watch for final FDA decision timeline and any potential approval conditions or post-marketing requirements
ReplimuneReplimune oncolytic immunotherapy (melanoma candidate)
→ Read original article